Latest Releases
U.S. Senator Tina Smith’s Bills to Reduce the Cost of Prescription Drugs and Expand Access to Health Care Signed Into Law
WASHINGTON, D.C. [1/13/23] — More than half a dozen health care bills by U.S. Senator Tina Smith (D-Minn.) were signed into law by President Biden two weeks ago. The measures will take important steps to lower the cost of prescription drugs, address public health workforce shortages, and shore up supply chains while creating good-paying American jobs. Most of the provisions were bipartisan. “Since my first day in office, I’ve promised Minnesotans that I would work to reduce the cost of prescription drugs and expand access to health care,” said Sen. Smith. “These measures provide the tools to make significant progress on lowering health care costs, boosting our public health workforce, and more.” These new laws will: Require the Department of Health and Human Services (HHS) to establish a program to improve health outcomes and reduce health inequities. Help speed up the development of and improve access to lower-cost generic drugs by requiring the Food and Drug Administration (FDA) to make timely therapeutic equivalence evaluations for drugs approved through the complex generic pathway. This provision is based on Smith’s Modernizing Therapeutic Equivalence Rating Determination Act. Clarify the FDA’s ability to regulate combination products—products that meet both the definition of drugs and devices—as drugs rather than as devices. The provision is based on Smith’s Consistent Legal Evaluation and Regulation of Medical Products (CLEAR) Act and will eliminate unnecessary confusion and turmoil in the industry. This clarification will allow the FDA to spend more time and resources on bringing low-cost products to market to
U.S. Senator Tina Smith’s Bipartisan Mental Health Care Measures Signed Into Law
WASHINGTON, D.C. [1/13/23] — U.S. Senator Tina Smith (D-Minn.) announced two of her bipartisan mental health care bills were signed into law by President Biden two weeks ago. The provisions will take important steps to address the mental health crisis and improve Tribal health services. “I know firsthand the importance of mental health services. These measures will help expand access to mental health care in Minnesota and across this country,” said Sen. Smith. “It gives us the tools to make significant progress tackling the mental health crisis, upholding our commitments to Tribal Nations, and more.” Provisions based on Smith’s Improving Access to Behavioral Health Integration Act will provide funding for primary care practices to implement evidence-based behavioral health integration programs. In addition, the law will establish grants for Tribal governments, Tribal organizations, urban Indian organizations, and Tribal health programs to receive funds for culturally-competent mental and behavioral health services for Native Americans. The bills were included in the year-end government funding package that was recently signed into law. In addition to Smith’s mental health bills, the law also includes many other important provisions supported by Sen. Smith such as the Electoral Count Reform Act, support for the people of Ukraine, fully funding provisions of the PACT Act, permanently extending postpartum coverage for mothers on Medicaid and CHIP, increasing child care and housing access, and more.
Sen. Tina Smith’s Statement on Senate Net Neutrality Vote
WASHINGTON, D.C. [05/16/18]—Today, U.S. Sen. Tina Smith (D-Minn.) voted to restore net neutrality protections that were recently overturned by President Trump’s Federal Communications Commission (FCC). “I’ve heard from Minnesotans across the state, including large and small businesses, educators, and health care providers that a free and open internet is critically important to their bottom line and to our state’s economic future. They strongly oppose the creation of fast lanes and slow lanes dictated by companies like Comcast and Verizon.” said Sen. Smith. “Today’s vote continues our efforts to restore protections for an open internet that millions of people across the country need
Bipartisan, bicameral bill from Sens. Coons, Risch, Smith, Gardner & Reps Luján, Fleischmann, Hultgren, Lipinski supports small business innovation
WASHINGTON – U.S. Senators Chris Coons (D-DE), James Risch (R-ID), Tina Smith (D-MN), and Cory Gardner (R-CO) and U.S. Representatives Ben Ray Luján (D-NM), Chuck Fleischmann (R-TN), Randy Hultgren (R-IL), and Daniel Lipinski (D-IL) today introduced the Promoting Small Business Innovation through Partnerships with National Labs Act, which allows small businesses to gain access to premier facilities at the national labs, spurring innovation and stimulating the culture of private-public collaboration. Small businesses are the lifeblood of the American economy. However, the cost of investing in necessary but expensive capital equipment often prohibits small businesses from pursuing truly innovative ideas and developing
Sen. Tina Smith Says Minnesotans Deserve to Know How Drug Companies Are Using Billions in Tax Breaks
WASHINGTON, D.C. [05/17/18]—Today, U.S. Senator Tina Smith is introducing legislation that would require pharmaceutical companies to share with Minnesotans and people across the country how they’re using the billions of dollars in tax breaks they received as a result of the Republican tax bill. The GOP tax law provided pharmaceutical companies with large windfalls that could have been used to bring down costs for consumers. But earlier this year, news reports showed that some top pharmaceutical companies used a large chunk of their tax cuts to benefit investors and drive up stocks. Sen. Smith’s bill—the Disclosing Pharmaceutical Company Windfall Profits Act—would make
Sen. Tina Smith Pressing for Senate Hearing on Novartis Payments to Trump Lawyer Michael Cohen
WASHINGTON, D.C. [05/17/18]—U.S. Senator Tina Smith (D-Minn.) is calling for a full investigation of the payments Novartis made to President Trump’s personal attorney Michael Cohen and is asking the leaders of the Senate Health Committee to hold a hearing with the CEO of Novartis as the key witness. Sen. Smith expresses concern that the payments may have played a role in shaping the Trump Administration’s positions on issues affecting Novartis and other drug makers, including importation of cheaper drugs from abroad. You can read a copy of the letter Sen. Smith sent by clicking here. “Discovery of these payments comes at
English